

COVID-19 incidence not increased with corticosteroid injections

July 14 2022



Adults who received image-guided corticosteroid injections for

musculoskeletal pain between April 2020 and February 2021 had a lower incidence of symptomatic COVID-19 than the general population in Massachusetts, according to a study published online July 5 in *Radiology*.

Joao R.T. Vicentini, M.D., from Massachusetts General Hospital in Boston, and colleagues examined the incidence of symptomatic COVID-19 in individuals receiving image-guided [corticosteroid](#) injections for musculoskeletal pain between April 2020 and February 2021 in a prospective cohort multicenter study. A total of 2,190 adult participants underwent 2,714 corticosteroid injections; follow-up data were available for 1,960 adults who received 2,484 injections. The Massachusetts COVID-19 Response Reporting website was used to obtain the incidence of COVID-19 in the state during the same period.

The researchers found that 0.5 and 2.2 percent of participants had COVID-19 within 28 days of the corticosteroid [injection](#) and up to four months after the injection, respectively. This was lower than the [general population](#) incidence rate of COVID-19, which was 7.5 percent in the population of Massachusetts during the same period. Compared with the entire cohort that received corticosteroid injections, participants with COVID-19 at 28 days had elevated body mass index.

"These findings provide reassurance to providers and individuals who rely on corticosteroid injections for the management of [musculoskeletal pain](#) during potential new COVID-19 surges, even in places with low vaccination rates," the authors write.

More information: Joao R. T. Vicentini et al, The Relationship of Imaging-guided Corticosteroid Injections to COVID-19 Incidence in the Pandemic Recovery Period, *Radiology* (2022). [DOI: 10.1148/radiol.220271](#)

Citation: COVID-19 incidence not increased with corticosteroid injections (2022, July 14)
retrieved 11 May 2024 from <https://medicalxpress.com/news/2022-07-covid-incidence-corticosteroid.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.